Flumazenil: mechanism and seizure risk
Flumazenil reverses the drowsiness caused by benzodiazepines (sedatives such as diazepam) by competing with them at their receptor site, but it can precipitate (trigger) seizures.
Remember
Flumazenil rapidly reverses benzodiazepine sedation (drowsiness), but it can precipitate seizures, particularly in long-term benzodiazepine users or in a mixed overdose that includes a proconvulsant (a drug that makes seizures more likely). It is usually reserved for clearly iatrogenic overdose (caused by medical treatment), such as midazolam given for a procedure.
Memory aid
the benzodiazepine as a seat belt holding seizures back, and flumazenil as the thing that unbuckles it
It shows why removing the benzodiazepine's effect can let seizures through.
Benzodiazepines (sedatives such as diazepam and midazolam) act on the GABA-A receptor, a receptor for GABA. GABA is the main inhibitory (calming) neurotransmitter in the brain, meaning a chemical messenger that quietens neurones. Benzodiazepines bind to the receptor and boost the calming effect of GABA, and that boost is what causes sedation (drowsiness).
Flumazenil reverses this. It is a competitive antagonist: it takes up the benzodiazepine binding site on the GABA-A receptor without switching the receptor on. Competitive means that flumazenil and the benzodiazepine share one binding spot: flumazenil displaces the benzodiazepine, and more benzodiazepine can displace flumazenil. Sedation reverses rapidly.
The difficulty is that benzodiazepines also have an anticonvulsive (seizure-suppressing) effect. Removing them suddenly can precipitate seizures, meaning trigger them. In long-term benzodiazepine users, flumazenil removes the drug's effect abruptly, which can bring on acute withdrawal, including withdrawal seizures. The risk also rises when a proconvulsant (a drug that makes seizures more likely) is taken as well, such as a tricyclic antidepressant (an older antidepressant that is dangerous in overdose). The benzodiazepine may have been masking those seizures, and flumazenil can unmask them.
Flumazenil has a short half-life (the time for a drug's blood level to halve), so re-sedation (the drowsiness returning) is common once the effect wears off. Because of the seizure risk, it is usually reserved for a clearly iatrogenic overdose, one caused by medical treatment, such as midazolam given for a procedure.
Key facts
- Mechanism
- it displaces the benzodiazepine at its binding site on the GABA-A receptor, so sedation reverses rapidly.
- Main risk
- seizures can be precipitated, particularly in long-term benzodiazepine users and in a mixed overdose that includes a proconvulsant such as a tricyclic antidepressant.
- Half-life
- it is short, so re-sedation is common once the effect wears off.
- Best fit
- it is usually reserved for clearly iatrogenic overdose, meaning one caused by medical treatment, such as midazolam given for a procedure.
- Tricyclic clues
- a wide QRS complex (the part of the ECG that records the ventricles firing), hypotension and seizures point to tricyclic toxicity, which is a warning sign before giving flumazenil.
Exam traps
- A long half-life is not the recognised problem with flumazenil: its half-life is short, so re-sedation as the effect wears off is the more usual one.
- Flumazenil does not add to respiratory depression after benzodiazepines: it reverses benzodiazepine-induced respiratory depression, although slow breathing still calls for airway and breathing support.
- Calling flumazenil a non-competitive antagonist is wrong: it competes at the benzodiazepine site, so it displaces the drug and does reverse sedation.
Read the full notes
Tested in 6 SimpleMed+ questions
Practice it in Pharmacology, with the answer and a full explanation after every question.
Practice these questions